ERBB2 and breast carcinoma: In HER2-overexpressing breast cancer, one emerging explanation for resistance to trastuzumab is the presence of the ERBB2d16 isoform, which contains a 16-amino-acid in-frame deletion in the juxta transmembrane domain (Figure 1A).